1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
MedlineGoogle Scholar
2. Zheng M. Classification and pathology of lung cancer. Surg. Oncol. Clin. N. Am. 25, 447–468 (2016).
MedlineGoogle Scholar
3. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Protocolos clínicos e diretrizes terapêuticas em oncologia (2014). http://bvsms.saude.gov.br/bvs/publicacoes/protocolos_clinicos_diretrizes_terapeuticas_oncologia.pdf
Google Scholar
4. Caley ACR, Jones R. The principles of cancer treatment by chemotherapy. Surgery (Oxford) 30, 186–190 (2012).
Google Scholar
5. World Health Organization. Glossary. In: Safety Monitoring of Medical Products: Reporting system for the general public (2012). https://www.who.int/medicines/areas/quality_safety/safety_efficacy/EMP_ConsumerReporting_web_v2.pdf”
Google Scholar
6. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364–378 (2014).
Medline CASGoogle Scholar
7. de Castria TB, da Silva EM, Gois AF et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small-cell lung cancer. Cochrane Database Syst. Rev. 8, CD009256 (2013).
Google Scholar
8. Visacri MB, Ferrari GB, Dias P et al. Quality of life of patients with squamous cell carcinoma of the head and neck receiving high-dose cisplatin chemotherapy and radiotherapy. South. Med. J. 108, 343–349 (2015).
Medline CASGoogle Scholar
9. Griesinger F, Korol EE, Kayaniyil S et al. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small-cell lung cancer: a meta-analysis. Lung Cancer 135, 196–204 (2019).
MedlineGoogle Scholar
10. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597–610 (2010).
Medline CASGoogle Scholar
11. Wang W, Shi Q, Mattes WB et al. Translating extracellular microRNA into clinical biomarkers for drug-induced toxicity: from high-throughput profiling to validation. Biomark. Med. 9, 1177–1188 (2015).
CASGoogle Scholar
12. Koturbash I, Tolleson WH, Guo L et al. MicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark. Med. 9, 1153–1176 (2015).
CASGoogle Scholar
13. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan – a web and mobile app for systematic reviews. Syst. Rev. 5, 210 (2016).
MedlineGoogle Scholar
14. Fang C, Li XP, Gong WJ et al. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy. Clin. Exp. Pharmacol. Physiol. 44(Suppl. 1), 21–29 (2017).
Medline CASGoogle Scholar
15. Pavkovic M, Robinson-Cohen C, Chua AS et al. Detection of drug-induced acute kidney injury in humans using urinary KIM-1, miR-21, -200c, and -423. Toxicol. Sci. 152, 205–213 (2016).
Medline CASGoogle Scholar
16. Quintanilha JCF, Cursino MA, Borges JB et al. MiR-3168, miR-6125, and miR-4718 as potential predictors of cisplatin-induced nephrotoxicity in patients with head and neck cancer. BMC Cancer 21, 575 (2021).
Medline CASGoogle Scholar

Vol. 15, No. 13

Metrics

Downloaded 81 times

History

Received 1 June 2021

Accepted 3 June 2021

Published online 17 August 2021

Published in print September 2021

Information

Keywords

Author contributions

P Moriel contributed with conception of the work. PENS Vasconcelos and EC Pincinato selected the articles of the scoping review. PENS Vasconcelos, CS Seguin, L Zambon, AS Barbeiro and MW Perroud Junior contributed with the patient acquisition. PENS Vasconcelos performed the microarray experiments. PENS Vasconcelos, MB Visacri and NG Torso wrote the manuscript. P Moriel and EC Pincinato revised the manuscript. All authors have read and agreed with the final version of the manuscript.

Acknowledgments

The authors would like to thank the librarian Ana Paula de Moraes e Oliveira (School of Medical Sciences of University of Campinas) for all the support offered for conducting the scoping review.

Financial & competing interests disclosure

This work was supported by the Universidade Presbiteriana Mackenzie (CI.FMP. 106/2018), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (finance code 001) and Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/13250–1). MB Visacri is a recipient of a postdoctoral scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) (88887.504453/2020–00). PENS Vasconcelos is a recipient of a doctoral scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES). CS Seguin is a recipient of a doctoral scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES). NG Torso is a recipient of a masters scholarship from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (2019/20010–7). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The study was approved by the Research Ethics Committee of the School of Medical Sciences of the University of Campinas (UNICAMP) (no. 83196318.8.0000.5404).

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/bmm-2021-0443

PDF download